Search

Search Constraints

You searched for: Author/Creator Lefkowitz, Martin

Search Results

11. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. (June 2016)

13. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Issue 14 (9th September 2022)

14. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). (April 2018)

15. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. (1st April 2014)

16. Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial. (1st July 2021)

18. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. (14th May 2020)

19. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial. (15th August 2022)